HealthGuard Biomed Secures National High-Tech Enterprise Certification and Files IPO Prospectus

HSGDHSGD is a leading enterprise in China's minimally invasive glaucoma sector. Its "Trabecular Micro-Bypass Stent System" product targets patients with open-angle glaucoma and is one of the smallest Class III implants globally. The product entered the National Medical Device Innovation Fast-Track in February 2024, breaking foreign technological monopolies and filling the gap for such products in China.

HSGD Awarded High-Tech Enterprise Certification

GOOD

  NEWS

Heat

Fierce

Best Wishes

Congratulations

Congratulations to HSGD on being awarded the "National High-tech Enterprise" certification!

Recently, HSGD (Suzhou) Biomedical Technology Co., Ltd. has successfully passed the National High-tech Enterprise certification and officially obtained the National High-tech Enterprise certificate. This recognition is an authoritative endorsement of HSGD's comprehensive capabilities in technological innovation, transformation of scientific research achievements, and enterprise growth in the field of integrated glaucoma diagnosis and treatment. It also represents a significant outcome of HSGD's commitment to innovation-driven development.

In the future,HSGD will continueIncrease R&D investment, strengthen core technology and product competitiveness, and adhere toWith a patient-centered初心, relying on ultra-micro precision production capabilities and a full-scenario product layout, HSGD provides an integrated solution for glaucoma diagnosis and treatment from preoperative screening, intraoperative therapy to postoperative management. This enhances the international discourse power of glaucoma research in China, allowing innovative technologies to benefit more patients.

About HSGD

With every bit of our effort, we protect every glimmer of hope for the patients!

HSGD Biomedical Technology Group, with bases in Shanghai, Suzhou, and Nantong, has been awarded the title of China's "Potential Unicorn" enterprise for 2023 and 2024; it has also received honors such as the 14th Leading Talent of Suzhou Industrial Park.

Currently, the company has grown into one of the leading enterprises in China’s minimally invasive glaucoma sector. Its product, the "Trabecular Meshwork Ultra-Micro Stent Drainage System," targets patients with open-angle glaucoma and is one of the smallest Class III implants globally. In February 2024, this product entered the National Medical Device Innovation Fast-Track Approval Process, breaking foreign technological monopolies and filling the gap for such products in China.